Ignite Creation Date:
2024-05-06 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05339217
Status:
RECRUITING
Last Update Posted:
2024-04-03
First Post:
2022-04-02
Brief Title:
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
Sponsor:
Liu Tian
Organization:
Peking University Peoples Hospital
Study Overview
Official Title:
Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus a Randomise Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to explore the clinical and immunological efficacy of Telitacicept and low dose IL-2 on systemic lupus erythematosus
Detailed Description:
Given that Telitacicept and low dose IL2 have been widespreadly applied in the treatment of systemic lupus erythematosus this study designed a randomised single center prospective study to investigate the effects and safety of combined utilization of Telitacicept and low dose IL-2 160mg Telitacicept and 1 million IU IL2 were regularly administered according to different circumstances Then the investigators evaluated the improvement of clinical and laboratory indexes and monitored the changes of immune cell subsets and cytokines
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None